Alaunos Therapeutics To Present Early Data From TCR-T Library Phase 1/2 Trial At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
Alaunos Therapeutics will present early data from its Phase 1/2 trial of TCR-T cell therapy at the 2023 ASCO Meeting. The therapy targets TP53 and KRAS driver mutations in solid tumors and has shown a manageable safety profile. The non-viral Sleeping Beauty cell engineering platform has demonstrated proof-of-concept in manufacturing TCR-T cell therapies.
May 25, 2023 | 9:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alaunos Therapeutics' TCR-T cell therapy shows promising early results in Phase 1/2 trial, targeting TP53 and KRAS mutations in solid tumors. Data to be presented at 2023 ASCO Meeting.
The early data from Alaunos Therapeutics' TCR-T cell therapy Phase 1/2 trial shows promising results, targeting TP53 and KRAS mutations in solid tumors. This positive news is likely to have a short-term positive impact on the company's stock price, as it demonstrates the potential of their therapy and the non-viral Sleeping Beauty cell engineering platform.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100